Experimental donor immune cells target Hard-to-Treat lymphoma

NCT ID NCT06285422

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests SC262, a therapy made from donor immune cells (CAR T cells) designed to attack a protein called CD22 on lymphoma cells. It is for people with non-Hodgkin's lymphoma that has come back or not responded to standard treatments. The main goal is to check safety, but researchers will also look for signs that the therapy shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
SC262 (a type of immune cell therapy called CAR T cells, made from donor cells)
What this could lead to
If it works, this could offer a new treatment option for people with non-Hodgkin's lymphoma that has not responded to other therapies.
What could go wrong
This is a very early (Phase 1) and small study (6 participants). It primarily tests safety, not effectiveness. The therapy may not work or could cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH-GRADE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Fred Hutchinson Cancer Center

    Seattle, Washington, 98109, United States

  • Swedish Cancer Institute

    Seattle, Washington, 98104, United States

  • The University of Kansas Hospital

    Kansas City, Kansas, 66160, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.